Acadia Pharmaceutica (ACAD)

$23.80 -1.04 (-4.19%)
Market Cap 4.19B
Revenue (ttm) 957.80M
Net Income (ttm) 226.45M
EPS (ttm) N/A
PE Ratio 39.67
Forward PE 48.59
Profit Margin 23.64%
Debt to Equity Ratio 0.00
Volume 2,193,800
Avg Vol 1,879,450
Day's Range N/A - N/A
Shares Out 168.71M
Stochastic %K 4%
Beta 0.75
Analysts Strong Sell
Price Target $29.84

Company Profile

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimava...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 558 2871
Fax: 858 212 0513
Address:
12830 El Camino Real, Suite 400, San Diego, United States
raylin
raylin Sep. 10 at 9:24 PM
$ACAD WTF is going on? Catalysts coming, upgrade, etc.
0 · Reply
TragicTrafic
TragicTrafic Sep. 10 at 6:50 PM
$ACAD Resistance acting like a suggestion, not a rule — NXXT marching through with metronome precision 🥁
0 · Reply
Quantumup
Quantumup Sep. 10 at 6:13 PM
Baird reiterated $SLNO Outperform/$121. Baird said: No change to outlook on FAERS update. The FAERS database was updated and now tragically has a listed death due to pulmonary embolism in a patient who was 17 years old, which management noted in an 8-K was considered by the physician to be not related to Vykat XR. Given comorbidities likely increasing baseline risk (lymphedema, superficial thrombophlebitis, obesity) and the physician's report as unrelated, we think the selloff here is far overdone and presents an even more attractive opportunity for investors to buy the launch on sale. $AARD $RYTM $ACAD $BIIB
0 · Reply
Quantumup
Quantumup Sep. 10 at 5:54 PM
TD Cowen reiterated $SLNO Buy/$120. TD Cowen said in its note: Three new SAEs for Vykat XR were uploaded to the FAERS database, which included a highly unfortunate death related to pulmonary embolism. The reporting physician does not consider this event as treatment-related, and $SLNO's assessment is the same. Pulmonary embolism risk is significantly increased in PWS and obese patients, and per our dinner with management last night, safety remains consistent. $AARD $RYTM $ACAD $BIIB
0 · Reply
kikmontero
kikmontero Sep. 10 at 4:45 PM
$ACAD Bought some
0 · Reply
outlawinvestor1
outlawinvestor1 Sep. 10 at 4:23 PM
$SLNO i'm not that surprised by today's dip. retracing from overbought bullish sentiment post-approval/launch + upcoming potential competition $ACAD $HRMY $RYTM
0 · Reply
HorizonBull
HorizonBull Sep. 10 at 2:17 PM
$ACAD
0 · Reply
HorizonBull
HorizonBull Sep. 9 at 4:54 PM
$ACAD nice added 500 24.70
0 · Reply
raylin
raylin Sep. 9 at 4:17 PM
$ACAD Go down on an upgrade? WTF!
2 · Reply
HorizonBull
HorizonBull Sep. 9 at 3:06 PM
$ACAD no brainer 40+ EOY
0 · Reply
Latest News on ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 8, 2025, 4:05 PM EDT - 2 days ago

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ACADIA Pharmaceuticals Inc. (ACAD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 8, 2025, 4:04 PM EDT - 2 days ago

ACADIA Pharmaceuticals Inc. (ACAD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Aug 26, 2025, 4:05 PM EDT - 15 days ago

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer

Aug 25, 2025, 4:05 PM EDT - 16 days ago

Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer

ACADIA Pharmaceuticals Inc. (ACAD) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 3:57 AM EDT - 5 weeks ago

ACADIA Pharmaceuticals Inc. (ACAD) Q2 2025 Earnings Call Transcript

Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview

Aug 6, 2025, 4:05 PM EDT - 5 weeks ago

Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

Aug 5, 2025, 4:05 PM EDT - 5 weeks ago

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer

Aug 4, 2025, 4:05 PM EDT - 5 weeks ago

Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer

Acadia Pharmaceuticals: ACP-101 Read-Out Is Not Fully Priced In

Jul 28, 2025, 4:32 AM EDT - 6 weeks ago

Acadia Pharmaceuticals: ACP-101 Read-Out Is Not Fully Priced In

Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025

Jul 23, 2025, 4:05 PM EDT - 7 weeks ago

Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025

Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers

Jun 25, 2025, 8:00 AM EDT - 2 months ago

Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers

U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent

Jun 9, 2025, 4:01 PM EDT - 3 months ago

U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent

Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025

Jun 5, 2025, 9:05 AM EDT - 3 months ago

Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025

Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

May 29, 2025, 4:05 PM EDT - 3 months ago

Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise

May 27, 2025, 4:05 PM EDT - 3 months ago

Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise

These Analysts Boost Their Forecasts On Acadia Pharmaceuticals

May 19, 2025, 8:25 AM EDT - 4 months ago

These Analysts Boost Their Forecasts On Acadia Pharmaceuticals

Acadia Pharmaceuticals: Another Legal Win, ACP-101 Readout Preview

May 17, 2025, 10:00 AM EDT - 4 months ago

Acadia Pharmaceuticals: Another Legal Win, ACP-101 Readout Preview

Delaware District Court Rules in Favor of Acadia in NUPLAZID® (pimavanserin) Formulation Patent Litigation

May 16, 2025, 1:43 PM EDT - 4 months ago

Delaware District Court Rules in Favor of Acadia in NUPLAZID® (pimavanserin) Formulation Patent Litigation

ACADIA Pharmaceuticals: Advancing On Several Fronts

May 13, 2025, 12:01 PM EDT - 4 months ago

ACADIA Pharmaceuticals: Advancing On Several Fronts

ACADIA Pharmaceuticals Inc. (ACAD) Q1 2025 Earnings Conference Call Transcript

May 7, 2025, 8:10 PM EDT - 4 months ago

ACADIA Pharmaceuticals Inc. (ACAD) Q1 2025 Earnings Conference Call Transcript

Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview

May 7, 2025, 4:05 PM EDT - 4 months ago

Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview

Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care Conference

May 5, 2025, 4:05 PM EDT - 4 months ago

Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care Conference

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025

Apr 23, 2025, 4:05 PM EDT - 5 months ago

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025

Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med

Mar 5, 2025, 9:05 AM EST - 6 months ago

Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med

Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study

Mar 3, 2025, 9:05 AM EST - 6 months ago

Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study

Acadia Pharmaceuticals Ends FY2024 On Solid Footing

Mar 2, 2025, 5:19 AM EST - 6 months ago

Acadia Pharmaceuticals Ends FY2024 On Solid Footing

Acadia Pharmaceuticals to Participate in the TD Cowen's 45th Annual Health Care Conference

Feb 27, 2025, 4:05 PM EST - 6 months ago

Acadia Pharmaceuticals to Participate in the TD Cowen's 45th Annual Health Care Conference

ACADIA Pharmaceuticals Inc. (ACAD) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 8:13 PM EST - 7 months ago

ACADIA Pharmaceuticals Inc. (ACAD) Q4 2024 Earnings Call Transcript

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

Feb 26, 2025, 4:05 PM EST - 7 months ago

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Feb 12, 2025, 4:05 PM EST - 7 months ago

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference

Jan 14, 2025, 9:05 AM EST - 8 months ago

Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference

Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome

Jan 14, 2025, 9:00 AM EST - 8 months ago

Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome

Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025

Dec 19, 2024, 4:05 PM EST - 9 months ago

Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025

Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

Dec 11, 2024, 4:05 PM EST - 9 months ago

Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer

Dec 9, 2024, 9:00 AM EST - 9 months ago

Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer

Acadia: Scope Of Company Goes Beyond Recent SAN711 Licensing Deal For ET

Nov 27, 2024, 3:18 PM EST - 10 months ago

Acadia: Scope Of Company Goes Beyond Recent SAN711 Licensing Deal For ET

Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711

Nov 26, 2024, 4:05 PM EST - 10 months ago

Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711

Acadia Pharmaceuticals: Proving The Naysayers Wrong

Nov 11, 2024, 10:50 AM EST - 10 months ago

Acadia Pharmaceuticals: Proving The Naysayers Wrong

ACADIA Pharmaceuticals Inc. (ACAD) Q3 2024 Earnings Conference Call Transcript

Nov 6, 2024, 8:09 PM EST - 11 months ago

ACADIA Pharmaceuticals Inc. (ACAD) Q3 2024 Earnings Conference Call Transcript

Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview

Nov 6, 2024, 4:05 PM EST - 11 months ago

Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview

Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million

Nov 5, 2024, 4:05 PM EST - 11 months ago

Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million

Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024

Oct 17, 2024, 6:41 PM EDT - 11 months ago

Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024

Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome

Oct 16, 2024, 4:07 PM EDT - 11 months ago

Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome

Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals

Sep 23, 2024, 4:15 PM EDT - 1 year ago

Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals

Axcelead Drug Discovery Partners Enters into Master Service Agreement for Drug Discovery Projects with Acadia Pharmaceuticals

Sep 19, 2024, 12:00 PM EDT - 1 year ago

Axcelead Drug Discovery Partners Enters into Master Service Agreement for Drug Discovery Projects with Acadia Pharmaceuticals

Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again

Aug 26, 2024, 3:02 PM EDT - 1 year ago

Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again

Ryan Reynolds Announces More to Parkinson's® Campaign

Aug 14, 2024, 8:04 AM EDT - 1 year ago

Ryan Reynolds Announces More to Parkinson's® Campaign

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference

Aug 7, 2024, 4:30 PM EDT - 1 year ago

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference

ACADIA Pharmaceuticals Inc. (ACAD) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 10:15 PM EDT - 1 year ago

ACADIA Pharmaceuticals Inc. (ACAD) Q2 2024 Earnings Call Transcript

Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview

raylin
raylin Sep. 10 at 9:24 PM
$ACAD WTF is going on? Catalysts coming, upgrade, etc.
0 · Reply
TragicTrafic
TragicTrafic Sep. 10 at 6:50 PM
$ACAD Resistance acting like a suggestion, not a rule — NXXT marching through with metronome precision 🥁
0 · Reply
Quantumup
Quantumup Sep. 10 at 6:13 PM
Baird reiterated $SLNO Outperform/$121. Baird said: No change to outlook on FAERS update. The FAERS database was updated and now tragically has a listed death due to pulmonary embolism in a patient who was 17 years old, which management noted in an 8-K was considered by the physician to be not related to Vykat XR. Given comorbidities likely increasing baseline risk (lymphedema, superficial thrombophlebitis, obesity) and the physician's report as unrelated, we think the selloff here is far overdone and presents an even more attractive opportunity for investors to buy the launch on sale. $AARD $RYTM $ACAD $BIIB
0 · Reply
Quantumup
Quantumup Sep. 10 at 5:54 PM
TD Cowen reiterated $SLNO Buy/$120. TD Cowen said in its note: Three new SAEs for Vykat XR were uploaded to the FAERS database, which included a highly unfortunate death related to pulmonary embolism. The reporting physician does not consider this event as treatment-related, and $SLNO's assessment is the same. Pulmonary embolism risk is significantly increased in PWS and obese patients, and per our dinner with management last night, safety remains consistent. $AARD $RYTM $ACAD $BIIB
0 · Reply
kikmontero
kikmontero Sep. 10 at 4:45 PM
$ACAD Bought some
0 · Reply
outlawinvestor1
outlawinvestor1 Sep. 10 at 4:23 PM
$SLNO i'm not that surprised by today's dip. retracing from overbought bullish sentiment post-approval/launch + upcoming potential competition $ACAD $HRMY $RYTM
0 · Reply
HorizonBull
HorizonBull Sep. 10 at 2:17 PM
$ACAD
0 · Reply
HorizonBull
HorizonBull Sep. 9 at 4:54 PM
$ACAD nice added 500 24.70
0 · Reply
raylin
raylin Sep. 9 at 4:17 PM
$ACAD Go down on an upgrade? WTF!
2 · Reply
HorizonBull
HorizonBull Sep. 9 at 3:06 PM
$ACAD no brainer 40+ EOY
0 · Reply
JarvisFlow
JarvisFlow Sep. 9 at 2:47 PM
UBS has updated their rating for ACADIA Pharmaceuticals ( $ACAD ) to Buy with a price target of 39.
0 · Reply
zeustony88
zeustony88 Sep. 9 at 2:19 PM
$ACAD UBS Adjusts Price Target on ACADIA Pharmaceuticals to $39 From $36, Maintains Buy Rating
1 · Reply
copywrites
copywrites Sep. 9 at 12:24 PM
$ACAD early q4 = top line results (p3) of PWS -> ACP-101 q1'26 following NDA filing and later 2026 potential approval 👀
0 · Reply
HorizonBull
HorizonBull Sep. 5 at 2:51 PM
$ACAD added 1k at 25.20
0 · Reply
zeustony88
zeustony88 Sep. 3 at 6:00 PM
$ACAD Is it 4th quarter yet? Will be here before you know it. I trust Ms. Adams
0 · Reply
MadMusk
MadMusk Sep. 2 at 9:17 AM
$ACAD will it ever close gap to 50
1 · Reply
zeustony88
zeustony88 Aug. 29 at 12:40 PM
$ACAD https://finance.yahoo.com/news/acadia-pharmaceuticals-inc-acad-nears-085338380.html?fr=sycsrp_catchall
1 · Reply
SanKish
SanKish Aug. 29 at 7:41 AM
$ACAD waiting patiently… for the news to drop
0 · Reply
raylin
raylin Aug. 27 at 10:29 PM
$ACAD Drop some news and take out $30.
0 · Reply
Bigeyes2
Bigeyes2 Aug. 27 at 10:07 PM
$ACAD Cup and handle
0 · Reply
zeustony88
zeustony88 Aug. 27 at 1:49 PM
$ACAD "On August 25, 2025, Acadia Pharmaceuticals announced the appointment of Konstantina (“Tina”) Katcheves as Senior Vice President, Chief Business and Strategy Officer, bringing her extensive leadership experience from Teva Pharmaceuticals and Bristol Myers Squibb. Katcheves’s proven record in advancing major pharmaceutical transactions and expanding innovative pipelines highlights Acadia’s intent to strengthen its growth and business development capabilities." .......This is such a huge addition to this company.
0 · Reply
zeustony88
zeustony88 Aug. 27 at 1:33 PM
$ACAD Stacking 52 week highs
0 · Reply